Sanofi-Aventis to end deal with PDI

Share this article:
Contract sales provider PDI said Sanofi-Aventis would end its $20 million sales agreement with the firm, effective Dec. 1. The deal was set to expire Dec. 31, PDI said. The end of the firm’s Sanofi-Aventis deal comes a month after GlaxoSmithKline decided not to renew a $65 million to $70 million contract with PDI for 2007. In April, AstraZeneca also ended a $65 million to $70 million agreement with PDI, affecting approximately 800 field representatives. PDI “has been significantly impacted” as the world’s top pharma companies re-evaluate their commercial models, CEO Michael Marquad said in a statement. “The decisions our customers have made have been based upon this reassessment and not related to the performance of our sales teams.”
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.